AR127371A2 - Receptores quiméricos de flt3 y métodos para usarlos - Google Patents
Receptores quiméricos de flt3 y métodos para usarlosInfo
- Publication number
- AR127371A2 AR127371A2 ARP220102800A ARP220102800A AR127371A2 AR 127371 A2 AR127371 A2 AR 127371A2 AR P220102800 A ARP220102800 A AR P220102800A AR P220102800 A ARP220102800 A AR P220102800A AR 127371 A2 AR127371 A2 AR 127371A2
- Authority
- AR
- Argentina
- Prior art keywords
- clone
- sequence
- amino acid
- seq
- heavy chain
- Prior art date
Links
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 title abstract 4
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 12
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 abstract 6
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 abstract 6
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 abstract 6
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 abstract 6
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 abstract 6
- 125000000539 amino acid group Chemical group 0.000 abstract 6
- 239000000427 antigen Substances 0.000 abstract 4
- 102000036639 antigens Human genes 0.000 abstract 4
- 108091007433 antigens Proteins 0.000 abstract 4
- 210000002865 immune cell Anatomy 0.000 abstract 4
- 239000013598 vector Substances 0.000 abstract 3
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 abstract 2
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- 108700010039 chimeric receptor Proteins 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/10—Protein-tyrosine kinases (2.7.10)
- C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Transplantation (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Rheumatology (AREA)
Abstract
Se divulgan moléculas de unión a antígenos, receptores quiméricos y células inmunes modificadas para FLT3 de acuerdo con la invención. La invención se relaciona además con vectores, composiciones y métodos de tratamiento y/o detección usando las moléculas de unión a antígenos de FLT3 y células inmunes modificadas. Reivindicación 1: Un receptor de un antígeno quimérico que comprende una molécula de unión al antígeno que se une específicamente a FLT3, caracterizado porque la molécula de unión al antígeno comprende: a) una CDR1 de la cadena pesada variable que comprende una secuencia de aminoácidos que no difiere en más de 3, 2, 1 ó 0 residuos de aminoácidos de la secuencia de la SEQ ID Nº 17; o b) una CDR2 de la cadena pesada variable que comprende una secuencia de aminoácidos que no difiere en más de 3, 2, 1 ó 0 residuos de aminoácidos de la secuencia de la SEQ ID Nº 18 o la SEQ ID Nº 26; o c) una CDR3 de la cadena pesada variable que comprende una secuencia de aminoácidos que no difiere en más de 3, 2, 1 ó 0 residuos de aminoácidos de la secuencia de la SEQ ID Nº 19 o la SEQ ID Nº 27; o d) una CDR1 de la cadena liviana variable que comprende una secuencia de aminoácidos que no difiere en más de 3, 2, 1 ó 0 residuos de aminoácidos de la secuencia de la SEQ ID Nº 22 o la SEQ ID Nº 30; o e) una CDR2 de la cadena liviana variable que comprende una secuencia de aminoácidos que no difiere en más de 3, 2, 1 ó 0 residuos de aminoácidos de la secuencia de la SEQ ID Nº 23 ó 31; o f) una CDR3 de la cadena liviana variable que comprende una secuencia de aminoácidos que no difiere en más de 3, 2, 1 ó 0 residuos de aminoácidos de la secuencia de la SEQ ID:24 o la SEQ ID Nº 32; o g) una CDR1 de la cadena pesada variable que comprende una secuencia de aminoácidos de una secuencia de la CDR1 de la cadena pesada variable del clon 10E3, del clon 2E7, del clon 8B5, del clon 4E9 o del clon 11F11; o h) una CDR2 de la cadena pesada variable que comprende una secuencia de aminoácidos de una secuencia de la CDR2 de la cadena pesada variable del clon 10E3, del clon 2E7, del clon 8B5, del clon 4E9 o del clon 11F11; o i) una CDR3 de la cadena pesada variable que comprende una secuencia de aminoácidos de una secuencia de la CDR3 de la cadena pesada variable del clon 10E3, del 2E7, del 8B5, del 4E9 o del 11F11; o j) una CDR1 de la cadena liviana variable que comprende una secuencia de aminoácidos de una secuencia de la CDR1 de la cadena liviana variable clon 10E3, del clon 2E7, del clon 8B5, del clon 4E9 o del clon 11F11; o k) una CDR2 de la cadena liviana variable que comprende una secuencia de aminoácidos de una secuencia de la CDR2 de la cadena liviana variable del clon 10E3, del clon 2E7, del clon 8B5, del clon 4E9 o del clon 11F11; o l) una CDR3 de la cadena liviana variable que comprende una secuencia de aminoácidos de una secuencia de la CDR3 de la cadena liviana variable del clon 10E3, del clon 2E7, del clon 8B5, del clon 4E9 o del clon 11F11; o m) una secuencia de la cadena pesada variable que no difiere en más de 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 ó 0 residuos de la secuencia de la cadena pesada variable del clon 10E3, del clon 2E7, del clon 8B5, del clon 4E9 o del clon 11F11; o n) una secuencia de la cadena liviana variable que no difiere en más de 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 ó 0 residuos de la secuencia de la cadena liviana variable del clon 10E3, del clon 2E7, del clon 8B5, del clon 4E9 o del clon 11F11. Reivindicación 12: Un polinucleótido, caracterizado porque codifica el receptor del antígeno quimérico de la reivindicación 1. Reivindicación 13: Un vector, caracterizado porque comprende al polinucleótido de la reivindicación 12. Reivindicación 15: Una célula inmune, caracterizada porque comprende el vector de la reivindicación 13. Reivindicación 21: Una composición farmacéutica, caracterizada porque comprende una célula inmune de la reivindicación 15.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662317219P | 2016-04-01 | 2016-04-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR127371A2 true AR127371A2 (es) | 2024-01-17 |
Family
ID=58530714
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP170100839A AR109626A1 (es) | 2016-04-01 | 2017-04-03 | Receptores quiméricos de flt3 y métodos para usarlos |
ARP220102800A AR127371A2 (es) | 2016-04-01 | 2022-10-14 | Receptores quiméricos de flt3 y métodos para usarlos |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP170100839A AR109626A1 (es) | 2016-04-01 | 2017-04-03 | Receptores quiméricos de flt3 y métodos para usarlos |
Country Status (26)
Country | Link |
---|---|
US (2) | US20190183931A1 (es) |
EP (1) | EP3436479A1 (es) |
JP (2) | JP2019516352A (es) |
KR (2) | KR102389096B1 (es) |
CN (1) | CN109641956A (es) |
AR (2) | AR109626A1 (es) |
AU (2) | AU2017240801A1 (es) |
BR (1) | BR112018070187A8 (es) |
CA (1) | CA3019655A1 (es) |
CL (1) | CL2018002792A1 (es) |
CO (1) | CO2018011804A2 (es) |
CR (1) | CR20180518A (es) |
EA (1) | EA201892193A1 (es) |
IL (2) | IL262061B2 (es) |
MA (1) | MA44507A (es) |
MX (1) | MX2023013729A (es) |
MY (1) | MY201207A (es) |
NZ (1) | NZ746925A (es) |
PE (2) | PE20241061A1 (es) |
PH (1) | PH12018502118A1 (es) |
SA (1) | SA518400154B1 (es) |
SG (2) | SG11201808622SA (es) |
TN (1) | TN2018000337A1 (es) |
TW (2) | TW202313669A (es) |
UA (1) | UA128326C2 (es) |
WO (1) | WO2017173410A1 (es) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201116559D0 (en) | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
US9725710B2 (en) | 2014-01-08 | 2017-08-08 | Flodesign Sonics, Inc. | Acoustophoresis device with dual acoustophoretic chamber |
US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
JOP20160086B1 (ar) | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
JOP20160198B1 (ar) | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
JO3633B1 (ar) | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
CA3013405A1 (en) | 2016-03-31 | 2017-10-05 | Janssen Pharmaceuticals, Inc. | Substituted indole derivatives as dengue viral replication inhibitors |
ES2923771T3 (es) | 2016-03-31 | 2022-09-30 | Janssen Pharmaceuticals Inc | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue |
US10730884B2 (en) | 2016-04-01 | 2020-08-04 | Janssen Pharmaceuticals, Inc. | Substituted indole compound derivatives as dengue viral replication inhibitors |
JOP20170069B1 (ar) | 2016-04-01 | 2021-08-17 | 1 Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
AR108066A1 (es) | 2016-04-01 | 2018-07-11 | Kite Pharma Inc | Receptores quiméricos para cll-1 y métodos de uso de los mismos |
EP3436036A4 (en) | 2016-04-01 | 2020-03-18 | Kite Pharma, Inc. | BCMA-BINDING MOLECULES AND METHOD FOR USE THEREOF |
MX2018012017A (es) * | 2016-04-01 | 2019-07-04 | Kite Pharma Inc | Antigeno quimerico y receptores de celulas t y metodos de uso. |
US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
US11236171B2 (en) | 2016-12-21 | 2022-02-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies specific for FLT3 and uses thereof |
JOP20180025B1 (ar) | 2017-03-31 | 2021-08-17 | Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
JOP20180026A1 (ar) | 2017-03-31 | 2019-01-30 | Univ Leuven Kath | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
EA201992782A1 (ru) | 2017-05-22 | 2020-03-24 | Янссен Фармасьютикалз, Инк. | Замещенные производные индолина в качестве ингибиторов репликации вирусов денге |
DK3630724T3 (da) | 2017-05-22 | 2021-07-26 | Janssen Pharmaceuticals Inc | Substituerede indolinderivater som inhibitorer af virusreplikation af denguevirus |
MX2019013923A (es) * | 2017-06-02 | 2020-01-21 | Pfizer | Receptores de antigenos quimericos que se dirigen a flt3. |
MA56289B1 (fr) | 2017-08-03 | 2022-04-29 | Amgen Inc | Mutéines d'interleukine-21 et méthodes de traitement |
IL272512B (en) | 2017-09-08 | 2022-07-01 | Amgen Inc | kras g12c inhibitors and methods of using them |
MA51631A (fr) | 2018-01-12 | 2020-11-18 | Amgen Inc | Anticorps anti-pd1 et méthodes de traitement |
WO2019180724A1 (en) * | 2018-03-23 | 2019-09-26 | Gavish-Galilee Bio Applications Ltd. | Genetically reprogrammed tregs expressing membrane-bound il-10 |
MA52203A (fr) * | 2018-04-10 | 2021-02-17 | Amgen Inc | Récepteurs chimères pour dll3 et leurs procédés d'utilisation |
CN112292400A (zh) | 2018-04-13 | 2021-01-29 | 桑格摩生物治疗法国公司 | 对白介素-23受体特异的嵌合抗原受体 |
EP3952886A1 (en) * | 2019-04-10 | 2022-02-16 | Elevatebio Technologies, Inc | Flt3-specific chimeric antigen receptors and methods of using the same |
WO2020223445A1 (en) | 2019-04-30 | 2020-11-05 | Senti Biosciences, Inc. | Chimeric receptors and methods of use thereof |
CN115066248A (zh) * | 2019-12-16 | 2022-09-16 | 华盛顿大学 | 嵌合抗原受体树突状细胞(car-dc)及其制备和使用方法 |
IL297236A (en) * | 2020-04-17 | 2022-12-01 | Hope City | Cells modified with a flt3-specific chimeric antigen receptor for the treatment of flt3-positive cancers |
CN111808821B (zh) * | 2020-06-24 | 2022-06-14 | 南方医科大学珠江医院 | Flt3-nkg2d双靶点car-t的构建与制备 |
US20220227832A1 (en) | 2020-12-21 | 2022-07-21 | Allogene Therapeutics, Inc. | Protease-activating cd45-gate car |
CA3204357A1 (en) * | 2021-01-28 | 2022-08-04 | Todd LUMAN | Methods for transducing immune cells |
EP4284918A1 (en) | 2021-01-29 | 2023-12-06 | Allogene Therapeutics, Inc. | Knockdown or knockout of one or more of tap2, nlrc5, beta2m, trac, rfx5, rfxap and rfxank to mitigate t cell recognition of allogeneic cell products |
CN116410315A (zh) * | 2021-12-31 | 2023-07-11 | 博生吉医药科技(苏州)有限公司 | 一种新型靶向人flt3的嵌合抗原受体修饰的t细胞的构建及应用 |
US20240042030A1 (en) | 2022-07-29 | 2024-02-08 | Allogene Therapeutics, Inc. | Engineered cells with reduced gene expression to mitigate immune cell recognition |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US6319494B1 (en) | 1990-12-14 | 2001-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
US5830462A (en) | 1993-02-12 | 1998-11-03 | President & Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
US5869337A (en) | 1993-02-12 | 1999-02-09 | President And Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
US5834266A (en) | 1993-02-12 | 1998-11-10 | President & Fellows Of Harvard College | Regulated apoptosis |
US20030036654A1 (en) | 1994-08-18 | 2003-02-20 | Holt Dennis A. | Synthetic multimerizing agents |
US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
EP1257632B1 (en) | 2000-02-24 | 2007-09-12 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
US7446190B2 (en) * | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
TWI615407B (zh) * | 2005-08-26 | 2018-02-21 | 羅齊克雷雅公司 | 具有經改變細胞傳訊活性之改質抗原結合分子 |
US20100196336A1 (en) | 2006-05-23 | 2010-08-05 | Dongsu Park | Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods |
HUE028629T2 (en) * | 2009-12-23 | 2016-12-28 | Synimmune Gmbh | Anti-FLT3 antibodies and ways of their use |
US9089520B2 (en) | 2010-05-21 | 2015-07-28 | Baylor College Of Medicine | Methods for inducing selective apoptosis |
DK2649086T3 (en) | 2010-12-09 | 2017-09-18 | Univ Pennsylvania | USING CHEMICAL ANTIGEN RECEPTOR-MODIFIED T-CELLS TO TREAT CANCER |
AU2012209103B2 (en) | 2011-01-26 | 2015-12-03 | Takeda Pharmaceutical Company Limited | Methods and compositions for the synthesis of multimerizing agents |
CN103502438A (zh) | 2011-03-23 | 2014-01-08 | 弗雷德哈钦森癌症研究中心 | 用于细胞免疫治疗的方法和组合物 |
PT3613439T (pt) | 2013-02-15 | 2021-05-12 | Univ California | Recetor de antigénio quimérico e métodos de utilização do mesmo |
EP2968502B1 (en) | 2013-03-14 | 2020-08-26 | Bellicum Pharmaceuticals, Inc. | Methods for controlling t cell proliferation |
DK3027204T3 (da) | 2013-07-29 | 2022-04-19 | 2Seventy Bio Inc | Flerdelte signaleringsproteiner og anvendelser deraf |
WO2015090229A1 (en) | 2013-12-20 | 2015-06-25 | Novartis Ag | Regulatable chimeric antigen receptor |
WO2015123527A1 (en) | 2014-02-14 | 2015-08-20 | Bellicum Pharmaceuticals, Inc. | Methods for activating t cells using an inducible chimeric polypeptide |
US20170335281A1 (en) * | 2014-03-15 | 2017-11-23 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
CA2956471A1 (en) * | 2014-07-31 | 2016-02-04 | Amgen Research (Munich) Gmbh | Optimized cross-species specific bispecific single chain antibody constructs |
KR102683584B1 (ko) * | 2014-09-19 | 2024-07-10 | 시티 오브 호프 | IL13Rα2를 표적화하는 공자극 키메라 항원 수용체 T 세포 |
-
2017
- 2017-03-31 SG SG11201808622SA patent/SG11201808622SA/en unknown
- 2017-03-31 NZ NZ746925A patent/NZ746925A/en unknown
- 2017-03-31 SG SG10201911963VA patent/SG10201911963VA/en unknown
- 2017-03-31 CA CA3019655A patent/CA3019655A1/en active Pending
- 2017-03-31 BR BR112018070187A patent/BR112018070187A8/pt unknown
- 2017-03-31 TN TNP/2018/000337A patent/TN2018000337A1/en unknown
- 2017-03-31 IL IL262061A patent/IL262061B2/en unknown
- 2017-03-31 MY MYPI2018001669A patent/MY201207A/en unknown
- 2017-03-31 PE PE2023001958A patent/PE20241061A1/es unknown
- 2017-03-31 EP EP17716764.0A patent/EP3436479A1/en active Pending
- 2017-03-31 UA UAA201810056A patent/UA128326C2/uk unknown
- 2017-03-31 CN CN201780033054.XA patent/CN109641956A/zh active Pending
- 2017-03-31 CR CR20180518A patent/CR20180518A/es unknown
- 2017-03-31 KR KR1020187031715A patent/KR102389096B1/ko active IP Right Grant
- 2017-03-31 WO PCT/US2017/025613 patent/WO2017173410A1/en active Application Filing
- 2017-03-31 PE PE2018001940A patent/PE20190201A1/es unknown
- 2017-03-31 IL IL296966A patent/IL296966A/en unknown
- 2017-03-31 KR KR1020227012842A patent/KR20220054453A/ko not_active Application Discontinuation
- 2017-03-31 JP JP2018551409A patent/JP2019516352A/ja active Pending
- 2017-03-31 AU AU2017240801A patent/AU2017240801A1/en not_active Abandoned
- 2017-03-31 MA MA044507A patent/MA44507A/fr unknown
- 2017-03-31 EA EA201892193A patent/EA201892193A1/ru unknown
- 2017-03-31 US US16/090,562 patent/US20190183931A1/en not_active Abandoned
- 2017-04-03 AR ARP170100839A patent/AR109626A1/es unknown
- 2017-04-05 TW TW111130070A patent/TW202313669A/zh unknown
- 2017-04-05 TW TW106111460A patent/TWI776807B/zh active
-
2018
- 2018-10-01 CL CL2018002792A patent/CL2018002792A1/es unknown
- 2018-10-01 MX MX2023013729A patent/MX2023013729A/es unknown
- 2018-10-01 PH PH12018502118A patent/PH12018502118A1/en unknown
- 2018-10-01 SA SA518400154A patent/SA518400154B1/ar unknown
- 2018-10-31 CO CONC2018/0011804A patent/CO2018011804A2/es unknown
-
2022
- 2022-01-10 AU AU2022200108A patent/AU2022200108A1/en active Pending
- 2022-03-09 JP JP2022035975A patent/JP2022091793A/ja active Pending
- 2022-05-23 US US17/751,586 patent/US20230124464A1/en active Pending
- 2022-10-14 AR ARP220102800A patent/AR127371A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR127371A2 (es) | Receptores quiméricos de flt3 y métodos para usarlos | |
AR108066A1 (es) | Receptores quiméricos para cll-1 y métodos de uso de los mismos | |
CL2019001926A1 (es) | Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017). | |
PE20190120A1 (es) | Moleculas de union a bcma y metodos de uso de las mismas | |
PE20221580A1 (es) | Anticuerpos terapeuticos y sus usos | |
AR101829A1 (es) | Tratamiento de cáncer utilizando un receptor quimérico de antígeno cll-1 | |
EA202091710A1 (ru) | Антитела против cd73 и способы их применения | |
MX2023007045A (es) | Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) y metodos de uso de los mismos. | |
PE20181451A1 (es) | Anticuerpos neutralizadores del virus de inmunodeficiencia humana | |
PE20220495A1 (es) | Receptores antigenicos quimericos y agentes de union dirigidos a dll3 | |
PE20171654A1 (es) | Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer | |
AR106184A1 (es) | Proteínas de unión a pd-1 y sus métodos de uso | |
MD4716B1 (ro) | Anticorpi anti-LAG3 şi fragmente de legare a antigenului | |
AR106949A1 (es) | Polipéptidos biparatópicos que antagonizan la señalización wnt en células tumorales | |
PE20200610A1 (es) | Polipeptidos que antagonizan la senalizacion wnt en celulas tumorales | |
PE20180481A1 (es) | Anticuerpos de union a tau | |
PE20171180A1 (es) | Anticuerpos anti-pd-1 y sus metodos de uso | |
PE20181270A1 (es) | Anticuerpo que neutraliza el virus respiratorio sincitial humano | |
PE20190737A1 (es) | Anticuerpos anti-cd27 | |
PE20141908A1 (es) | Anticuerpos cd47 y metodos de uso los mismos | |
EA034770B8 (ru) | Человеческие антитела к pd-1 | |
PE20110225A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5 | |
AR075504A1 (es) | Moleculas de anticuerpos que tienen especificidad para el ox40 humano | |
AR096617A1 (es) | Anticuerpos anti-tweakr y sus usos | |
AR101875A1 (es) | Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp / receptor pac1 y usos de las mismas |